- Report
- January 2024
- 200 Pages
Global
From €4806EUR$5,000USD£4,121GBP
- Report
- March 2024
- 250 Pages
Global
From €2586EUR$2,690USD£2,217GBP
- Report
- May 2024
- 898 Pages
Global
From €5382EUR$5,600USD£4,616GBP
- Report
- January 2024
- 395 Pages
Global
From €7209EUR$7,500USD£6,182GBP
- Drug Pipelines
- April 2024
- 80 Pages
Global
From €2403EUR$2,500USD£2,061GBP
- Report
- August 2022
- 30 Pages
Global
From €2643EUR$2,750USD£2,267GBP
- Report
- July 2020
- 143 Pages
Global
From €6680EUR$6,950USD£5,728GBP
- Report
- January 2019
- 50 Pages
Global
From €1442EUR$1,500USD£1,236GBP
- Report
- August 2022
- 115 Pages
Global
From €4325EUR$4,500USD£3,709GBP
- Drug Pipelines
- July 2019
- 345 Pages
Global
€21145EUR$22,000USD£18,133GBP
- Clinical Trials
- May 2020
- 878 Pages
Global
From €2403EUR$2,500USD£2,061GBP
Epidiolex is a pharmaceutical drug used to treat certain types of epilepsy. It is the first FDA-approved drug derived from cannabidiol (CBD), a component of the cannabis plant. Epidiolex is used to treat two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. It is classified as a central nervous system (CNS) drug, which are drugs that act on the brain and spinal cord to treat neurological disorders.
Epidiolex is manufactured by GW Pharmaceuticals, a British biopharmaceutical company. It is distributed in the United States by Greenwich Biosciences, a subsidiary of GW Pharmaceuticals. Other companies in the CNS drug market include AbbVie, Allergan, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more
